Healthcare, Pharma & Life Sciences

NFID Survey: Half of US Adults Skip Respiratory Vaccines Despite Broad Support

Image
NFID Survey: Half of US Adults Skip Respiratory Vaccines Despite Broad Support

Washington – September 25, 2026 -- More than half of US adults did not attempt to get a flu, COVID-19, RSV, or pneumococcal vaccine in the past year, even though 77% agree vaccines are among the best proven tools against serious infectious disease, according to a new national survey released by the National Foundation for Infectious Diseases (NFID).

Survey finds 48% of adults tried to get at least one of four respiratory vaccines in the past year

The survey, conducted by NORC at the University of Chicago among 1,206 US adults age 18 and older between August 13-17, 2026, has a margin of sampling error of ±3.6 percentage points. Just 44% tried to get a flu vaccine and only 23% attempted a COVID-19 vaccine, despite 89% of respondents agreeing that anyone who wants vaccine access should have it and 71% saying benefits strongly outweigh risks.

E Tech Group to Address Lab Automation Compliance Gaps at ISPE Show

Image
E Tech Group to Address Lab Automation Compliance Gaps at ISPE Show

West Chester, Ohio – September 25, 2026 -- E Tech Group will present on the compliance and data integrity risks of scaling laboratory automation from pilot to full production at the ISPE Boston Area Chapter 2026 Product Show on October 7 at Gillette Stadium in Foxborough, Massachusetts.

Session targets the gap between pilot success and regulated production failure

Sura Hadi, Director of Laboratory Automation and Industrial Robotics (LAIR) at E Tech Group, will lead the 3:00 p.m. ET session, "From Pilot to Production: Scaling Lab Automation Without Breaking Compliance, Data Integrity, or Teams," in West Red Level, Suite 81. The talk addresses why automation pilots that succeed in contained workflows frequently break down when expanded into regulated manufacturing environments, where instruments must connect to scheduling systems, Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELN), and other enterprise platforms.

US Social Connection Survey Finds Persistent Loneliness, Weak Ties

Image
US Social Connection Survey Finds Persistent Loneliness, Weak Ties

Washington – September 25, 2026 -- Four in ten Americans report moderate to severe loneliness, according to the second annual Social Connection in AmericaTM survey, which found that key indicators of social connection weakened for a second consecutive year.

Nearly 70% of Americans see loved ones no more than once or twice a month

The survey, part of a 25-year national tracking initiative led by RAND and The Connection Institute with founding funder the Barnes Family Foundation, found that one in five Americans meet with people they care about only a few times a year or less. Time constraints are the top barrier to connection, cited by 30.6% of respondents, followed by distance (14.8%), effort (13.3%) and social anxiety (11.1%).

Sanyou Bio, NovoCodex Partner to Co-Develop Dual-Payload ADCs

Shanghai – September 25, 2026 -- Sanyou Biopharmaceuticals Co., Ltd. and NovoCodex Biopharmaceuticals Co., Ltd. have signed a strategic collaboration agreement to jointly develop next-generation antibody-drug conjugates (ADCs), combining Sanyou Bio's AI-driven antibody discovery platforms with NovoCodex's clinically validated site-specific conjugation technology.

NovoCodex brings a clinically validated conjugation platform to the partnership

NovoCodex's proprietary NovoCodeTM platform incorporates unnatural amino acids into antibodies to achieve defined, controllable conjugation sites, producing homogeneous ADC products rather than the heterogeneous mixtures typical of traditional random conjugation. The technology has been validated in the pivotal Phase III trial of ARX788 and supported ARX305 in showing a favorable safety window and durable antitumor activity in advanced renal cancer patients with high CD70 expression.

Clarius Repeats on TIME's Top 500 Global HealthTech List

Image
Clarius Repeats on TIME's Top 500 Global HealthTech List

Vancouver – September 25, 2026 -- Clarius Mobile Health has been named to TIME's list of the World's Top HealthTech Companies 2026 for the second consecutive year, placing it among just 500 companies selected from thousands reviewed globally.

TIME and Statista ranked Clarius on financial performance, reputation and online engagement

The list, presented by TIME and Statista Inc., was announced on September 25, 2026. Statista evaluated thousands of HealthTech companies worldwide before narrowing the field to the top 500 recognized for their performance across financial, reputational and engagement metrics.

Aqua Medical Closes Series B to Fund US Trial for Diabetes Device

Image
Aqua Medical Closes Series B to Fund US Trial for Diabetes Device

Pleasanton, Calif. – – September 25, 2026 -- Aqua Medical, Inc. has closed a Series B financing round led by Nashville-based Relevance Ventures, with proceeds earmarked to complete its ongoing U.S. RESTORE-1 pilot study and prepare for a planned U.S. pivotal trial of its investigational diabetes procedure.

Series B capital targets completion of RESTORE-1 pilot and pivotal trial launch

The financing will fund the remaining stages of the RESTORE-1 pilot study, which is evaluating Aqua Medical's Proximal Intestinal Mucosal Ablation (PIMA) procedure for Type 2 diabetes under an FDA-approved Investigational Device Exemption. The company said the round will also support operational preparations, including patient recruitment infrastructure, for a larger planned pivotal trial subject to regulatory authorization.

Moore Named Brand Agency of Record for Alzheimer's Association

Image
Moore Named Brand Agency of Record for Alzheimer's Association

Washington – September 25, 2026 -- Moore has been named brand agency of record for the Alzheimer's Association, expanding an existing fundraising mandate to now cover strategy, creative and media across the health organization's master brand.

Moore expands scope beyond fundraising into full brand management

The appointment follows a competitive review process and grants Moore oversight of all brand creative development, paid media planning and delivery, and marketing across the Association's master brand and national initiatives. The agency will also support select medical and scientific research communications, product launches, and campaigns aimed at reinforcing the Association's position in brain health.

81% of Senior Living Execs Report Rising Resident Acuity: Sage Report

Image
81% of Senior Living Execs Report Rising Resident Acuity: Sage Report

New York – September 25, 2026 -- Eighty-one percent of senior living executives say resident acuity has increased over the past two years, according to a new report from Sage, an integrated Care Intelligence Platform for senior living and skilled nursing. The findings, unveiled at Sage's caregiving summit Sage Shift, draw on a survey of 510 senior living executives, community leaders and caregivers conducted between July 9 and September 25, 2026, alongside operational data from communities running Sage's platform.

Atossa CEO Quay to Join Harvard Panel on Aging Drug Development

Image
Atossa CEO Quay to Join Harvard Panel on Aging Drug Development

Seattle – September 25, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that President and CEO Steven Quay, M.D., Ph.D., will serve as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), scheduled for October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston.

Quay joins regulatory and academic leaders to discuss clinical pathways for aging-related diseases

The panel, titled "Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways," is set for Thursday, September 25, 2026, from 11:20 a.m. to 12:00 p.m. ET. The session will be moderated by Sebastien Thuault, Editor at Nature Medicine, and will include Jill Lee, Director of Regulatory Policy & Intelligence at Novo Nordisk; Calum MacRae, Professor at Mass General Brigham; and Steve Horvath, Professor at UCLA.

Leapfrog Group Names Retired Navy VADM Raquel Bono Board Chair

Image
Leapfrog Group Names Retired Navy VADM Raquel Bono Board Chair

Washington – September 25, 2026 -- The Leapfrog Group, a national watchdog organization of employers and other health care purchasers, has elected Raquel Bono, MD, MBA, FACS, as its new Board Chair, marking the first time a surgeon has led the nonprofit's board.

Retired Navy Vice Admiral brings $50 billion health system oversight to Leapfrog's board

Dr. Bono is a board-certified trauma surgeon and retired three-star Vice Admiral in the U.S. Navy, where she served as the 11th Chief of the Navy Medical Corps. From 2015 to 2019, she directed the Defense Health Agency, overseeing integration of a $50 billion global health system serving millions of service members and their families.